rs1553619735
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4BS2_Supporting
The NM_000465.4(BARD1):c.1333G>A(p.Glu445Lys) variant causes a missense change. The variant allele was found at a frequency of 0.00000411 in 1,461,020 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000465.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.00000411 AC: 6AN: 1461020Hom.: 0 Cov.: 30 AF XY: 0.00000275 AC XY: 2AN XY: 726906
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:3
- -
This missense variant replaces glutamic acid with lysine at codon 445 of the BARD1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual affected with breast cancer (PMID: 29785153). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.E445K variant (also known as c.1333G>A), located in coding exon 5 of the BARD1 gene, results from a G to A substitution at nucleotide position 1333. The glutamic acid at codon 445 is replaced by lysine, an amino acid with similar properties. This alteration was reported in 1/130 Romanian breast cancer cases meeting NCCN criteria for genetic testing (Goidescu IG et al. Clujul Med, 2018 Apr;91:157-165). This alteration has also been reported in 2/1197 individuals with a personal and/or family history of breast and/or ovarian cancer (Tsaousis GN et al. BMC Cancer, 2019 Jun;19:535). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Familial cancer of breast Uncertain:2
- -
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 445 of the BARD1 protein (p.Glu445Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with breast cancer (PMID: 29785153, 31159747). ClinVar contains an entry for this variant (Variation ID: 479183). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not specified Uncertain:1
- -
not provided Uncertain:1
Not observed in large population cohorts (Lek 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 31159747, 29785153) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at